scholarly journals Boosting of Markers of Fcγ Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption

2019 ◽  
Vol 35 (9) ◽  
pp. 842-852
Author(s):  
Hugh Billings ◽  
Bruce D. Wines ◽  
Wayne B. Dyer ◽  
Robert J. Center ◽  
Halina M. Trist ◽  
...  
2019 ◽  
Vol 5 ◽  
pp. 49
Author(s):  
J. Martinez-Navio ◽  
R. Desrosiers ◽  
S. Fuchs ◽  
D. Mendes ◽  
E. Rakasz ◽  
...  

2009 ◽  
Vol 16 (7) ◽  
pp. 1060-1065 ◽  
Author(s):  
Odd Odinsen ◽  
David Parker ◽  
Frans Radebe ◽  
Mikey Guness ◽  
David A Lewis

ABSTRACT Diagnosis of acute human immunodeficiency virus (HIV) infection, a key driver of the HIV epidemic, remains a public health challenge. The PlasmAcute technology offers an opportunity to detect early anti-HIV antibody responses. B lymphocytes (B cells) were isolated from the blood of seronegative miners in South Africa by using the PlasmAcute method. B-cell lysates and paired sera were tested for anti-HIV-1 antibodies by two different enzyme-linked immunosorbent assays; immunoreactivity was confirmed by Western blotting. All volunteers were tested for HIV type 1 (HIV-1) viral load, p24 antigen, and CD4 count. Sera from HIV-seronegative men who had positive viral loads and were positive for p24 antigen were retested for anti-HIV antibodies after immune complex dissociation. Anti-HIV antibodies were detected in lysates from 16/259 subjects without immunoreactivity in paired sera. Four subjects, one of whom had a positive viral load initially, subsequently seroconverted. Six subjects showed transient anti-HIV-1 antibodies in the lysates and tested negative for all markers at the follow-up. Five subjects without follow-up data initially had lysate-positive/serum-negative samples, and these cases were classified as inconclusive. One subject had lysate antibodies and a detectable viral load but was seronegative at follow-up. In conclusion, lysate-derived anti-HIV-1 B-cell antibodies can be detected prior to seroconversion and earlier than or contemporary with HIV-1 RNA detection.


2021 ◽  
Vol 13 (607) ◽  
pp. eabf7201
Author(s):  
Ines Frank ◽  
Mariasole Cigoli ◽  
Muhammad S. Arif ◽  
Marissa D. Fahlberg ◽  
Stephanie Maldonado ◽  
...  

Anti-HIV broadly neutralizing antibodies (bNAbs) may favor development of antiviral immunity by engaging the immune system during immunotherapy. Targeting integrin α4β7 with an anti-α4β7 monoclonal antibody (Rh-α4β7) affects immune responses in SIV/SHIV-infected macaques. To explore the therapeutic potential of combining bNAbs with α4β7 integrin blockade, SHIVSF162P3-infected, viremic rhesus macaques were treated with bNAbs only (VRC07-523LS and PGT128 anti-HIV antibodies) or a combination of bNAbs and Rh-α4β7 or were left untreated as a control. Treatment with bNAbs alone decreased viremia below 200 copies/ml in all macaques, but seven of eight macaques (87.5%) in the bNAbs-only group rebounded within a median of 3 weeks (95% CI: 2 to 9). In contrast, three of six macaques treated with a combination of Rh-α4β7 and bNAbs (50%) maintained a viremia below 200 copies/ml until the end of the follow-up period; viremia in the other three macaques rebounded within a median of 6 weeks (95% CI: 5 to 11). Thus, there was a modest delay in viral rebound in the macaques treated with the combination antibody therapy compared to bNAbs alone. Our study suggests that α4β7 integrin blockade may prolong virologic control by bNAbs in SHIVSF162P3-infected macaques.


AIDS ◽  
2007 ◽  
Vol 21 (16) ◽  
pp. 2131-2139 ◽  
Author(s):  
Erin M Scherer ◽  
Michael B Zwick ◽  
Luc Teyton ◽  
Dennis R Burton
Keyword(s):  

1988 ◽  
Vol 51 (8) ◽  
pp. 1063-1068 ◽  
Author(s):  
K S Bukasa ◽  
C J Sindic ◽  
M Bodeus ◽  
G Burtonboy ◽  
C Laterre ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document